SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-060730
Filing Date
2023-03-06
Accepted
2023-03-06 08:10:56
Documents
3
Group Members
SUMITOMO PHARMA CO., LTD.SUMITOVANT BIOPHARMA LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d479268dsc13da.htm SC 13D/A 69910
2 EX-99.2 d479268dex992.htm EX-99.2 9867
3 GRAPHIC g479268g0302052253842.jpg GRAPHIC 4612
  Complete submission text file 0001193125-23-060730.txt   87934
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44 207-400-3351
Myovant Sciences Ltd. (Subject) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-89732 | Film No.: 23707628
SIC: 2834 Pharmaceutical Preparations

Mailing Address 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020
Business Address 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020 813-5201-0222
Sumitomo Chemical Co., Ltd. (Filed by) CIK: 0001798550 (see all company filings)

IRS No.: 980339148 | State of Incorp.: M0 | Fiscal Year End: 0331
Type: SC 13D/A